tiletamine hydrochloride has been researched along with dehydroxymethylepoxyquinomicin in 148 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 61 (41.22) | 29.6817 |
2010's | 79 (53.38) | 24.3611 |
2020's | 8 (5.41) | 2.80 |
Authors | Studies |
---|---|
Ariga, A; Inoue, J; Matsumoto, N; Namekawa, J; Umezawa, K | 1 |
Chaicharoenpong, C; Kato, K; Umezawa, K | 2 |
Chaicharoenpong, C; Umezawa, K | 1 |
Horiguchi, Y; Kikuchi, E; Kuroda, K; Murai, M; Nakashima, J; Ohigashi, T; Oya, M; Shima, Y; Takahashi, N; Umezawa, K | 1 |
Asano, T; Hayakawa, M; Kosaka, T; Miyajima, A; Seta, K; Umezawa, K | 1 |
Horiguchi, Y; Kuroda, K; Murai, M; Nakashima, J; Umezawa, K | 1 |
Maeda, S; Namba, H; Ohtsuru, A; Saenko, VA; Starenki, DV; Umezawa, K; Yamashita, S | 1 |
Dewan, MZ; Higashihara, M; Honda, M; Horie, R; Itoh, K; Mizoguchi, H; Okamura, T; Sasaki, M; Sata, T; Umezawa, K; Watanabe, M; Watanabe, T; Yamamoto, N | 1 |
Bando, H; Matsumoto, G; Muta, M; Nakamura, T; Namekawa, J; Tohyama, K; Toi, M; Umezawa, K | 1 |
Aoki, K; Asagiri, M; Kubota, T; Ohya, K; Oka, K; Osada, T; Saito, H; Sugiyama, C; Takatsuna, H; Takayanagi, H; Umezawa, K | 1 |
Horie, R; Ishida, A; Ishida, T; Kumasaka, T; Ohsugi, T; Umezawa, K; Urano, T; Watanabe, T; Yamaguchi, K | 1 |
Morita, S; Nagatsu, T; Sawada, M; Takatsuna, H; Umezawa, K | 1 |
Aizawa, S; Higashihara, M; Horie, R; Ishida, T; Kamihira, S; Kikuchi, H; Koga, S; Maruyama-Nagai, M; Ohsugi, T; Okayama, A; Shoda, M; Umezawa, K; Uozumi, K; Utsunomiya, A; Watanabe, M; Watanabe, T; Yamada, Y; Yamaguchi, K | 1 |
Horie, R; Ishida, A; Ishida, T; Kumasaka, T; Ohsugi, T; Umezawa, K; Watanabe, T; Yamaguchi, K | 1 |
Hata, H; Matsuno, F; Mitsuya, H; Nakamura, M; Okuno, Y; Sonoki, T; Taniguchi, I; Tatetsu, H; Umezawa, K; Uneda, S | 1 |
Horiguchi, Y; Kanao, K; Kikuchi, E; Kuroda, K; Miyajima, A; Murai, M; Nakashima, J; Ohigashi, T; Umezawa, K | 1 |
Matsumoto, G; Misumi, K; Muta, M; Okamoto, A; Suzuki, T; Toi, M; Tsuruta, K; Umezawa, K | 1 |
Kubota, T; Miyasaka, N; Nanki, T; Umezawa, K; Wakamatsu, K | 1 |
Ito, A; Komune, S; Kuratomi, Y; Masuda, M; Nakashima, T; Ruan, HY; Umezawa, K; Weinstein, IB; Yamamoto, T; Yasumatsu, R | 1 |
Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T | 1 |
Hayakawa, M; Horiguchi, Y; Ito, K; Mizuno, R; Murai, M; Oya, M; Sato, A; Umezawa, K | 1 |
Alaimo, A; Carina, V; Cervello, M; Cusimano, A; D'Alessandro, N; Labbozzetta, M; Maurici, A; Notarbartolo, M; Poma, P; Sanguedolce, R | 1 |
Horie, R; Umezawa, K; Watanabe, T | 1 |
Eguchi, K; Fukuta, M; Goto, T; Hamasaki, K; Ichikawa, T; Ishikawa, H; Kawashimo, H; Matsumoto, K; Motoyoshi, Y; Nakao, K; Nishimura, D; Shibata, H; Taura, N; Umezawa, K | 1 |
Umezawa, K | 3 |
Suzuki, E; Umezawa, K | 1 |
Chiba, T; Ishigami, A; Kaneko, E; Kondo, Y; Maruyama, N; Shimokado, K; Shinozaki, S; Umezawa, K | 1 |
Aoyagi, T; Furukawa, H; Haga, S; Itoh, T; Ozaki, M; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S; Ueki, S; Umezawa, K; Yamashita, K | 1 |
Utsunomya, A | 1 |
Cervello, M; D'Alessandro, N; Giannitrapani, L; Labbozzetta, M; Montalto, G; Notarbartolo, M; Poma, P | 1 |
Dewan, MZ; Higashihara, M; Honda, M; Horie, R; Kadin, ME; Sata, T; Shoda, M; Taira, M; Umezawa, K; Watanabe, M; Watanabe, T; Yamamoto, N | 1 |
Ikeda, Y; Kimura, N; Kizaki, M; Kohmura, K; Miyakawa, Y; Umezawa, K | 1 |
Inoue, M; Ishida, S; Izumi-Nagai, K; Koto, T; Nagai, N; Oike, Y; Ozawa, Y; Satofuka, S; Tsubota, K; Umezawa, K; Yamashiro, K | 1 |
Horie, R; Ishida, T; Kumasaka, T; Ohsugi, T; Okada, S; Umezawa, K; Watanabe, T; Yamaguchi, K | 1 |
Ikeda, Y; Kawai, Y; Ohno, O; Sakurai, K; Shima, Y; Umezawa, K; Watanabe, K | 1 |
Namba, H; Saenko, V; Yamashita, S | 1 |
Aoki, K; Hoshino, M; Komano, Y; Kubota, T; Miyasaka, N; Nanki, T; Ohya, K; Umezawa, K | 1 |
Ikezoe, T; Jing, Y; Nishioka, C; Umezawa, K; Yokoyama, A | 1 |
Hirose, H; Horimai, C; Itoh, H; Miyashita, K; Saisho, Y; Takei, I; Umezawa, K | 1 |
Hirano, A; Makino, S; Mitsutake, N; Nakashima, M; Ohtsuru, A; Saenko, VA; Tanaka, K; Umezawa, K; Yamashita, S | 1 |
Dewan, MZ; Honda, M; Horie, R; Ishida, T; Miyake, A; Sata, T; Umezawa, K; Watanabe, M; Watanabe, T; Yamamoto, N | 1 |
Aoyagi, T; Fukai, M; Furukawa, H; Jomen, W; Ozaki, M; Suzuki, T; Todo, S; Ueki, S; Umezawa, K; Yamashita, K | 1 |
Ajima, H; Fukai, M; Furukawa, H; Kishino, S; Mochizuki, N; Ohno, K; Ozaki, M; Shiino, M; Todo, S; Umezawa, K; Watanabe, E | 1 |
Sugiyama, C; Suzuki, E; Umezawa, K | 1 |
Matsuse, M; Meng, Z; Mitsutake, N; Nakashima, M; Namba, H; Ohtsuru, A; Saenko, V; Starenki, D; Takakura, S; Umezawa, K; Yamashita, S | 1 |
Asano, T; Horiguchi, Y; Kikuchi, E; Kosaka, T; Miyajima, A; Nakashima, J; Ohigashi, T; Oya, M; Umezawa, K | 1 |
Horie, R; Kozawa, I; Takeiri, M; Umezawa, K; Yamamoto, M | 1 |
Horiuchi, K; Kawai, A; Morioka, H; Nakayama, R; Nishimoto, K; Ozaki, T; Sonobe, H; Susa, M; Suzuki, Y; Takaishi, H; Toyama, Y; Umezawa, K; Yabe, H | 1 |
Higashihara, M; Horie, R; Nakashima, M; Togano, T; Umezawa, K; Watanabe, M; Watanabe, T | 2 |
Bonavida, B; Huerta-Yepez, S; Jazirehi, AR; Martinez-Maza, O; Martinez-Paniagua, M; Umezawa, K; Vega, MI | 1 |
Ninomiya, Y; Suzuki, E; Umezawa, K | 1 |
Bonavida, B; Katsman, A; Umezawa, K | 1 |
Azzolina, A; Cervello, M; D'Alessandro, N; Lampiasi, N; McCubrey, JA; Montalto, G; Umezawa, K | 1 |
Dabaghmanesh, N; Horie, R; Ishida, T; Katano, H; Matsubara, A; Miyake, A; Nakano, K; Umezawa, K; Watanabe, T | 1 |
Chan, AT; Cheng, SH; Ho, Y; Lui, VW; Ng, MH; Tsang, CM; Tsao, SW; Umezawa, K; Wong, EY; Wong, JH | 1 |
Ishikawa, Y; Nishiyama, S; Obata, R; Saitoh, T; Suzuki, E; Takasugi, A; Umezawa, K | 1 |
Kato, K; Kozawa, I; Suenaga, K; Teruya, T; Umezawa, K | 1 |
Kawakami, Y; Okada, S; Onami, Y; Sasaki, Y; Tsukamoto, N; Umezawa, K | 1 |
Fukuya, Y; Hashimoto, R; Kanda, T; Kubota, T; Miyasaka, N; Nanki, T; Okamura, Y; Suzuki, H; Umezawa, K | 1 |
Higashihara, M; Horie, R; Nakashima, M; Sasaki, M; Togano, T; Tsuruo, T; Umezawa, K; Watanabe, M; Watanabe, T | 1 |
Barak, V; Chowers, I; Dror, R; Lederman, M; Pe'er, J; Umezawa, K | 1 |
Ishida, S; Iwabuchi, K; Iwata, D; Kitaichi, N; Miyazaki, A; Namba, K; Ohno, S; Onoé, K; Ozaki, M; Todo, S; Umezawa, K; Yamashita, K; Yoshida, K | 1 |
Aburatani, H; Gotoh, N; Hinohara, K; Isagawa, T; Kobayashi, S; Kuroda, M; Murohashi, M; Tojo, A; Tsuji, S; Umezawa, K | 1 |
Horiguchi, Y; Kanai, K; Kikuchi, E; Kodaira, K; Kosugi, M; Matsumoto, K; Miyajima, A; Nakagawa, K; Oya, M; Suzuki, E; Tachibana, M; Umezawa, K | 1 |
Hara, T; Horie, R; Ishida, T; Miyake, A; Umezawa, K; Watanabe, T; Yamagishi, M | 1 |
Caggia, S; Cardile, V; Frasca, G; Libra, M; Malaponte, G; Panico, A; Umezawa, K | 1 |
Bevelacqua, Y; Caggia, S; Cardile, V; Coco, M; Frasca, G; Libra, M; Malaponte, G; Mazzarino, MC; Stivala, F; Umezawa, K | 1 |
Kikuchi, E; Kono, H; Kosaka, T; Maeda, T; Miyajima, A; Mizuno, R; Nakagawa, K; Oya, M; Shinoda, K; Tanaka, N; Umezawa, K | 1 |
Abe, R; Hamasaka, A; Kishino, S; Ozaki, M; Shimizu, H; Todo, S; Umezawa, K; Yoshioka, N | 1 |
Furukawa, H; Kamachi, H; Kasai, H; Matsumoto, S; Matsushita, M; Ozaki, M; Takahashi, T; Todo, S; Tsuruga, Y; Umezawa, K; Watanabe, M | 1 |
Higashihara, M; Horie, R; Ishii, Y; Nakashima, M; Togano, T; Umezawa, K; Watanabe, M; Watanabe, T | 1 |
Ishikawa, Y; Nishiyama, S; Obata, R; Ohba, S; Saitoh, T; Shiino, M; Shimada, C; Takeiri, M; Umezawa, K | 1 |
Ishida, S; Kato, N; Kubota, M; Kubota, S; Kurihara, T; Miyashita, H; Noda, K; Ozawa, Y; Shimmura, S; Tsubota, K; Umezawa, K; Usui, T | 1 |
Kobayashi, K; Umezawa, K; Yasui, M | 1 |
Ninomiya, Y; Shimada, C; Suzuki, E; Umezawa, K | 1 |
Bobb, K; Datta, D; Jacobson, S; McCormick, MJ; Meshulam, J; Monie, DD; Oh, U; Sliskovic, DR; Tanaka, Y; Turner, RV; Zhang, J | 1 |
Haga, S; Kamiyama, T; Kataoka, A; Kina, M; Mino, K; Nakanishi, K; Ochiya, T; Ozaki, M; Sato, M; Takahashi, M; Takahashi, N; Todo, S; Umezawa, K; Yanagihara, K | 1 |
Kondo, S; Mukudai, Y; Nagumo, T; Shintani, S; Tsukamoto, H; Umezawa, K; Yasuda, A | 1 |
Goto, Y; Hakamata, M; Higashi, T; Niitsu, Y; Shoji, M; Sugai, T; Umezawa, K | 1 |
Ishida, T; Izawa, K; Kobayashi, S; Lin, SF; Tojo, A; Tsai, HJ; Umezawa, K; Watanabe, T | 1 |
Gotoh, Y; Ishikawa, Y; Nishiyama, S; Saitoh, T; Takeiri, M; Umezawa, K | 1 |
Isshiki, M; Tamura, H; Umezawa, K | 1 |
Fukushima, T; Kataoka, H; Kawaguchi, M; Takeshima, H; Tanaka, H; Umezawa, K; Yorita, K | 1 |
Adachi, Y; Ikehara, S; Kaneko, K; Okigaki, M; Shimo, T; Takaya, J; Taniuchi, S; Umezawa, K | 1 |
Alberti, C; Canevari, S; Ditto, A; Ferri, R; Pinciroli, P; Sensi, M; Tomassetti, A; Umezawa, K; Valeri, B | 1 |
Gondo, T; Horiguchi, Y; Nakashima, J; Ohno, Y; Tachibana, M; Takeuchi, H | 1 |
Fukai, M; Funakoshi, T; Goto, R; Ichihara, S; Ichikawa, N; Katsurada, T; Kobayashi, N; Oura, T; Ozaki, M; Suzuki, T; Todo, S; Umezawa, K; Yamashita, K | 1 |
Azzolina, A; Cervello, M; Lampiasi, N; McCubrey, JA; Montalto, G; Umezawa, K | 1 |
Aoyagi, T; Goto, R; Hirokata, G; Igarashi, R; Kobayashi, N; Oura, T; Ozaki, M; Shibasaki, S; Shibata, T; Todo, S; Ueki, S; Umezawa, K; Uno, M; Wakayama, K; Yamashita, K; Zaitsu, M | 1 |
Borges, KS; Castro-Gamero, AM; da Silva Silveira, V; de Paula Gomes Queiroz, R; Lira, RC; Scrideli, CA; Tone, LG; Umezawa, K; Valera, FC | 1 |
Horie, K; Horie, R; Simizu, S; Takahashi, D; Takeiri, M; Umezawa, K; Watanabe, M | 1 |
Kabe, Y; Kambayashi, Y; Noma, N; Simizu, S; Suematsu, M; Umezawa, K | 1 |
Anselmo-Lima, WT; Brassesco, MS; Castro-Gamero, AM; Queiroz, RG; Scrideli, CA; Tone, LG; Umezawa, K; Valera, FC | 1 |
Hasegawa, M; Horiguchi, Y; Ide, H; Kikuchi, E; Kozakai, N; Miyajima, A; Nakashima, J; Oya, M; Shigematsu, N; Suzuki, E; Umezawa, K | 1 |
Konno, S; Nishimura, M; Ozaki, M; Shimizu, K; Todo, S; Umezawa, K; Yamashita, K | 1 |
Hanaya, K; Kobayashi, R; Shoji, M; Sugai, T; Umezawa, K | 1 |
Aiura, K; Itano, O; Kitagawa, Y; Matsuda, S; Suzuki, K; Takeuchi, O; Umezawa, K | 1 |
Goto, R; Haga, S; Igarashi, R; Ozaki, M; Shibasaki, S; Todo, S; Tsunetoshi, Y; Umezawa, K; Wakayama, K; Yamashita, K; Zaitsu, M | 1 |
Belmadani, S; Bishop, A; Choi, SK; Galán, M; Kassan, M; Matrougui, K; Trebak, M; Umezawa, K | 1 |
Ito, A; Kawai, T; Ogasawara, A; Saisho, Y; Simizu, S; Takei, I; Umezawa, K | 1 |
Kojima, I; Sidthipong, K; Takei, I; Todo, S; Umezawa, K | 1 |
Adachi, Y; Ikehara, S; Kaneko, K; Kimata, T; Okigaki, M; Shimo, T; Takaya, J; Tsuji, S; Umezawa, K; Yamanouchi, S | 1 |
Gu, L; Johno, H; Kato, H; Kitamura, M; Nakajima, S; Takahashi, S; Umezawa, K | 1 |
Asahi, Y; Emoto, S; Kamachi, H; Koshizuka, Y; Kuraya, D; Matsushita, M; Ogura, M; Ono, H; Ozaki, M; Shibasaki, S; Todo, S; Umezawa, K; Watanabe, M; Yamashita, K; Yoshida, T | 1 |
Asahi, Y; Harashima, H; Kamachi, H; Koshizuka, Y; Kuraya, D; Matsushita, M; Nakamura, T; Ogura, M; Ozaki, M; Todo, S; Umezawa, K; Watanabe, M; Yamashita, K; Yoshida, T | 1 |
Ito, S; Koike, R; Komatsu, S; Kubota, T; Miyasaka, N; Shimogaki, S; Umezawa, K | 1 |
Higashihara, M; Horie, R; Itoh, K; Masuda, N; Togano, T; Umezawa, K; Watanabe, M | 1 |
Imamura, Y; Nagumo, S; Nakago, T; Takayama, K; Takeda, N; Yasui, E | 1 |
Belmadani, S; Choi, SK; Galán, M; Kassan, M; Matrougui, K; Trebak, M | 1 |
Aldinucci, D; Borghese, C; Carbone, A; Casagrande, N; Celegato, M; Colombatti, A; Umezawa, K | 1 |
Miyagi, T; Miyoshi, R; Ochiya, T; Oka, T; Shiotani, B; Tahara, H; Takano, M; Umezawa, K; Yamamoto, T | 1 |
Higashihara, M; Horie, R; Umezawa, K; Watanabe, M | 1 |
Aoki, D; Fujii, T; Iwata, T; Kawakami, Y; Kawamura, N; Kobayashi, A; Nishio, H; Park, J; Sugiyama, J; Sumimoto, H; Susumu, N; Umezawa, K; Yaguchi, T | 1 |
Baird, AM; Barr, MP; Cuffe, S; Finn, SP; Gately, K; Godwin, P; Heavey, S; O'Byrne, KJ; Umezawa, K | 1 |
Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Okada, S; Puapairoj, A; Pugkhem, A; Seubwai, W; Umezawa, K; Wongkham, C; Wongkham, S | 1 |
Baba, M; Fujiyoshi, M; Haga, S; Kamiyama, T; Mino, K; Nakanishi, K; Niwa, H; Ohmiya, Y; Ozaki, M; Sato, M; Taketomi, A; Todo, S; Umezawa, K; Yokoo, H | 1 |
Lian, A; Shi, Z; Zhang, F | 1 |
Fukuda, K; Fukushima, A; Hirakata, A; Inokawa, S; Keino, H; Okada, AA; Sato, Y; Umezawa, K; Watanabe, T | 1 |
Chen, TX; Jin, YY; Tian, ZQ; Wang, LL; Wang, XF; Wang, Z; Yang, WT; Yao, CM; Zhang, H | 1 |
Horie, K; Ma, J; Umezawa, K | 1 |
Asagiri, M; Iwaisako, K; Maeda-Yamamoto, M; Minato, N; Noma, N; Ohmae, S; Simizu, S; Takeiri, M; Takemoto, K; Umezawa, K | 1 |
Adachi, Y; Ikehara, S; Kaneko, K; Kuge, T; Li, M; Okigaki, M; Shimo, T; Takaya, J; Tsuji, S; Umezawa, K; Yamanouchi, S | 1 |
Kraiklang, R; Okada, S; Seubwai, W; Umezawa, K; Vaeteewoottacharn, K; Wongkham, S | 1 |
El-Salhy, M; Umezawa, K | 3 |
Fukushima, T; Kanemaru, A; Kataoka, H; Kawaguchi, M; Tanaka, H; Umezawa, K; Yamamoto, K | 1 |
Lin, Y; Okada, S; Ukaji, T; Umezawa, K | 1 |
D'Alessandro, N; Labbozzetta, M; Notarbartolo, M; Poma, P | 1 |
Dai, C; Gu, Y; Jiang, X; Lan, Y; Liu, X; Ma, J; Umezawa, K; Wei, B; Zhang, Y | 1 |
Benkisser-Petersen, M; Bleckmann, D; Burger, M; Claus, R; Decker, S; Dierks, C; Duyster, J; Foerster, K; Saleem, S; Simon-Gabriel, CP; Thornton, N; Umezawa, K; Veelken, H; Zirlik, K | 1 |
Castro-Gamero, AM; Oliveira, HF; Pezuk, JA; Ramos, PMM; Scrideli, CA; Tone, LG; Umezawa, K | 1 |
Koide, N; Lin, Y; Ukaji, T; Umezawa, K | 1 |
Fukatsu, H; Ichihara, S; Ikegami, A; Izuoka, K; Koide, N; Komatsu, T; Morita, N; Naiki, Y; Tada-Oikawa, S; Ukaji, T; Umezawa, K | 1 |
Gao, X; He, H; Jiang, X; Li, X; Ma, J; Ma, K; Umezawa, K; Wang, X; Xie, Z; Zhang, Y | 1 |
Ando, Y; Hirakata, A; Keino, H; Kudo, A; Okada, AA; Umezawa, K | 1 |
Chang, HW; Chiou, HY; Hsueh, CS; Jeng, CR; Pang, VF; Shih, CH; Wu, CH; Yeh, JL | 1 |
Lin, Y; Umezawa, K | 1 |
Ando, Y; Hirakata, A; Keino, H; Kudo, A; Okada, AA; Sato, Y; Umezawa, K; Watanabe, T | 1 |
He, X; Li, W; Li, X; Ma, J; Niu, N; Tao, H; Xia, Y; Xu, J; Xu, X | 1 |
Breborowicz, A; Gantsev, S; Umezawa, K | 1 |
Asanuma, H; Kanno, Y; Kono, H; Mizuno, R; Morita, S; Nakagawa, K; Oya, M; Shimoda, M; Shinoda, K; Umezawa, K; Yoshida, T | 1 |
El-Salhy, M; Keino, H; Kubota, T; Ma, J; Ozaki, M; Sugai, T; Umezawa, K; Zhang, Y | 1 |
Abe, Y; Fujisaki, H; Hasegawa, Y; Hori, S; Ishihara, K; Itano, O; Kishino, S; Kitagawa, Y; Kitago, M; Konno, T; Matsuda, S; Nakano, Y; Ohno, K; Suzuki, K; Tanaka, M; Umezawa, K; Yagi, H | 1 |
15 review(s) available for tiletamine hydrochloride and dehydroxymethylepoxyquinomicin
Article | Year |
---|---|
Molecular design and biological activities of NF-kappaB inhibitors.
Topics: Animals; Benzamides; Cyclohexanones; Drug Design; Humans; Mice; NF-kappa B; Signal Transduction | 2002 |
Antitumor effect of a novel nuclear factor-kappa B activation inhibitor in bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cyclohexanones; Humans; NF-kappa B; Urinary Bladder Neoplasms | 2003 |
Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cyclohexanones; Humans; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; NF-kappa B | 2006 |
Inhibition of tumor growth by NF-kappaB inhibitors.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Cyclohexanones; Drug Design; Humans; Neoplasms; NF-kappa B; Quinones; Signal Transduction; Tumor Cells, Cultured | 2006 |
[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
Topics: Benzamides; Boronic Acids; Bortezomib; Carrier State; Cyclohexanones; HIV Protease Inhibitors; Human T-lymphotropic virus 1; Humans; Infectious Disease Transmission, Vertical; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Ritonavir; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Nuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer.
Topics: Animals; Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Thyroid Neoplasms; Transcriptional Activation | 2007 |
[Screening of bioactive metabolites that suppress inflammation].
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Biological Products; Cell Differentiation; Cyclohexanones; Depsipeptides; Drug Design; Drug Evaluation, Preclinical; Inflammation; Inflammation Mediators; Lipopolysaccharides; Neoplasms; NF-kappa B; Osteoclasts; Piperidones; Signal Transduction | 2007 |
Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Neoplasm Metastasis; Neoplasms; NF-kappa B | 2009 |
Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cyclohexanones; Humans; Inflammation; Molecular Structure; Neoplasms; NF-kappa B; Peritoneum | 2011 |
[NF-kappaB inhibitor].
Topics: Antineoplastic Agents; Benzamides; Cyclohexanones; Glucocorticoids; Humans; Male; NF-kappa B; Prostatic Neoplasms; Proteasome Inhibitors; Pyrrolidines; Thiocarbamates | 2011 |
Screening of new bioactive metabolites for diabetes therapy.
Topics: Animals; Benzamides; Cell Differentiation; Cyclohexanones; Diabetes Mellitus, Type 1; Fibrosis; Humans; Insulin-Secreting Cells; Islets of Langerhans Transplantation; NF-kappa B; Vinca Alkaloids | 2013 |
Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.
Topics: Animals; Antineoplastic Agents; Benzamides; Cyclohexanones; Humans; Neoplasm Metastasis; Neoplasms; NF-kappa B; Quinones | 2018 |
Inhibition of matrix metalloproteinase expression and cellular invasion by NF-κB inhibitors of microbial origin.
Topics: Actinobacteria; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Movement; Cyclohexanones; Glyoxylates; Humans; Matrix Metalloproteinase 11; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Models, Molecular; Neoplasm Invasiveness; Neoplasms; NF-kappa B; NF-kappa B p50 Subunit; Quinones | 2020 |
Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration.
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cyclohexanones; Female; Humans; Injections, Intraperitoneal; Lymphoma; Male; Mice; Multiple Myeloma; Neoplasms; NF-kappa B | 2020 |
Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Cyclohexanones; Disease Models, Animal; Humans; Inflammation; Mice; NF-kappa B | 2021 |
133 other study(ies) available for tiletamine hydrochloride and dehydroxymethylepoxyquinomicin
Article | Year |
---|---|
Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.
Topics: Active Transport, Cell Nucleus; Apoptosis; Benzamides; Cyclohexanones; DNA-Binding Proteins; Genes, Reporter; Green Fluorescent Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Luminescent Proteins; Mitogen-Activated Protein Kinases; NF-kappa B; Phosphorylation; Smad2 Protein; Tetradecanoylphorbol Acetate; Trans-Activators; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha | 2002 |
Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF-kappaB functions.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Cyclohexanones; Dose-Response Relationship, Drug; Humans; Jurkat Cells; NF-kappa B; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2002 |
Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.
Topics: Animals; Apoptosis; Benzamides; Cell Division; Cyclohexanones; Dose-Response Relationship, Drug; Drug Resistance; Humans; Kinetics; Male; Mice; Mice, Nude; NF-kappa B; Prostatic Neoplasms; Tumor Cells, Cultured | 2003 |
Novel nuclear factor kappa B activation inhibitor prevents inflammatory injury in unilateral ureteral obstruction.
Topics: Animals; Apoptosis; Benzamides; Cell Division; Cyclohexanones; Fibrosis; In Situ Nick-End Labeling; Leukocyte Common Antigens; Leukocyte Count; NF-kappa B; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Ureter; Ureteral Obstruction | 2003 |
Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF-kappa B function inhibitor.
Topics: Benzamides; Cyclohexanones; Isotope Labeling; NF-kappa B; Tritium | 2003 |
Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Topics: Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Humans; NF-kappa B; Thyroid Neoplasms; Tumor Cells, Cultured | 2004 |
A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzamides; Calcium-Binding Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Line, Tumor; Cyclin D; Cyclin D1; Cyclins; Cyclohexanones; Disease Models, Animal; Down-Regulation; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Nerve Tissue Proteins; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Synaptotagmin I; Synaptotagmins; Translocation, Genetic; Vascular Endothelial Growth Factor A | 2005 |
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cyclohexanones; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Interleukin-6; Interleukin-8; Lymphotoxin-alpha; Male; Mice; Mice, Inbred BALB C; Mice, SCID; NF-kappa B; Phosphorylation; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2005 |
Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Topics: Animals; Benzamides; Bone Marrow Cells; Bone Resorption; Carrier Proteins; Cell Differentiation; Cyclohexanones; Down-Regulation; Macrophages; Membrane Glycoproteins; Mice; Mitogen-Activated Protein Kinases; Molecular Structure; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Phosphorylation; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B | 2005 |
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Binding Sites; Cell Division; Cell Line, Tumor; Consensus Sequence; Cyclohexanones; Disease Models, Animal; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Mice; NF-kappa B; Transplantation, Heterologous | 2005 |
Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
Topics: Animals; Benzamides; Cell Line; Cyclohexanones; Cytokines; Dose-Response Relationship, Drug; Interleukin-6; Lipopolysaccharides; Mice; Microglia; NF-kappa B; Tumor Necrosis Factor-alpha | 2005 |
Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Cycle; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Human T-lymphotropic virus 1; Humans; Immunoblotting; Immunohistochemistry; Jurkat Cells; K562 Cells; Leukemia-Lymphoma, Adult T-Cell; Leukemia, T-Cell; Leukocytes, Mononuclear; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Molecular Weight; NF-kappa B; Proviruses; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Time Factors; Tumor Suppressor Protein p53 | 2005 |
In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102.
Topics: Active Transport, Cell Nucleus; Animals; Benzamides; Cell Line; Cell Nucleus; Cyclohexanones; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Transcription Factor RelA | 2006 |
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cyclin D1; Cyclohexanones; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; I-kappa B Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Minor Histocompatibility Antigens; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2005 |
Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Benzamides; Body Mass Index; Body Weight; Cachexia; Cell Line, Tumor; Cyclohexanones; Disease Models, Animal; Dose-Response Relationship, Drug; Hematocrit; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Muscle, Skeletal; Neoplasm Transplantation; NF-kappa B; Prostatic Neoplasms; Time Factors; Triglycerides; Weight Loss | 2005 |
Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-kappaB inhibitor.
Topics: Apoptosis; Benzamides; Caspase 3; Caspases; Cell Survival; Cyclohexanones; Drug Interactions; Humans; Kinetics; Mitochondria; Pancreatic Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.
Topics: Animals; Arthritis, Experimental; Benzamides; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cyclohexanones; Disease Models, Animal; Hindlimb; Humans; Injections, Subcutaneous; Male; Mice; Mice, Inbred DBA; NF-kappa B; RNA, Messenger; Synovial Membrane; Translocation, Genetic | 2005 |
Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclohexanones; Gene Expression; Head and Neck Neoplasms; Humans; NF-kappa B; Vascular Endothelial Growth Factor A | 2006 |
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2006 |
Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor.
Topics: Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor I; Interferon-gamma; Kidney Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; RNA Interference; RNA, Small Interfering; Survivin; Transfection | 2006 |
Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Topics: Antineoplastic Agents; bcl-X Protein; Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cisplatin; Cyclohexanones; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Liver Neoplasms; Neuronal Apoptosis-Inhibitory Protein; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2006 |
DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.
Topics: Animals; Apoptosis; bcl-X Protein; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cyclohexanones; Electrophoretic Mobility Shift Assay; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Tumor Necrosis Factor-alpha | 2006 |
Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Topics: Animals; Benzamides; Cells, Cultured; Cyclohexanones; Cytokines; Lipopolysaccharides; Macrophage Activation; Mice; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Phagocytosis; Toll-Like Receptor 4 | 2006 |
A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice.
Topics: Adiponectin; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Benzamides; Body Weight; Cholesterol; Cyclohexanones; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Triglycerides; Tumor Necrosis Factor-alpha | 2006 |
Control of allograft rejection by applying a novel nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Topics: Animals; Antibodies, Monoclonal; Benzamides; CD28 Antigens; CD3 Complex; Cyclohexanones; Drug Therapy, Combination; Graft Rejection; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Male; Mice; Mice, Inbred Strains; NF-kappa B; Protein Transport; T-Lymphocytes; Tacrolimus | 2006 |
Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma.
Topics: Antibodies; Benzamides; Carcinoma, Hepatocellular; Cell Membrane; Curcumin; Cyclohexanones; Cytokine Receptor gp130; Humans; Interleukin-6; Liver Neoplasms; Models, Biological; NF-kappa B; Receptors, Interleukin-6; RNA, Small Interfering; Tumor Cells, Cultured | 2006 |
IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.
Topics: Animals; Apoptosis; Benzamides; Caspases; Cell Line; Cyclohexanones; Daunorubicin; Enzyme Activation; Etoposide; Hodgkin Disease; Humans; I-kappa B Kinase; I-kappa B Proteins; Leukocytes, Mononuclear; Mice; Mutation; Neoplasm Transplantation; NF-kappa B; NF-KappaB Inhibitor alpha; Reed-Sternberg Cells; Topoisomerase Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
Topics: Apoptosis; Benzamides; Burkitt Lymphoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Enzyme Activation; Humans; NF-kappa B; Phosphorylation | 2007 |
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzamides; Blotting, Western; Cell Adhesion; Chemokine CCL2; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Imidazoles; Intercellular Adhesion Molecule-1; Leukocytes; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Pyridines; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Retinitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazolidines; Valine; Valsartan; Vascular Endothelial Growth Factor A | 2007 |
Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with tax-deficient adult T-cell leukemia-derived cell lines.
Topics: Adult; Animals; Apoptosis; Benzamides; beta 2-Microglobulin; Cell Line, Tumor; Cyclohexanones; Gene Products, tax; Human T-lymphotropic virus 1; Humans; Leukemia, T-Cell; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2007 |
Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow.
Topics: Benzamides; Biomechanical Phenomena; Blotting, Western; Cell Adhesion; Cell Culture Techniques; Cells, Cultured; Cyclohexanones; Electrophoretic Mobility Shift Assay; Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Leukocytes; NF-kappa B; Tumor Necrosis Factor-alpha; Umbilical Veins | 2005 |
NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
Topics: Aged; Animals; Arthritis, Experimental; Benzamides; Cells, Cultured; Cyclohexanones; Female; Gene Expression Regulation; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Inbred DBA; Middle Aged; NF-kappa B; NFATC Transcription Factors; Osteoclasts; Osteoprotegerin; RANK Ligand | 2007 |
DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Benzamides; Cell Differentiation; Cell Proliferation; Cyclohexanones; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endocytosis; Humans; Jurkat Cells; Leukocytes, Mononuclear; Lymphocyte Culture Test, Mixed; Phytohemagglutinins; Th1 Cells | 2008 |
Effects of DHMEQ, a novel nuclear factor-kappab inhibitor, on beta cell dysfunction in INS-1 cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Survival; Cyclohexanones; Dose-Response Relationship, Drug; Glucose; Insulin; Insulin-Secreting Cells; Insulinoma; NF-kappa B; Pancreatic Neoplasms; Rats; Tumor Necrosis Factor-alpha | 2008 |
DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts.
Topics: Benzamides; Cell Division; Cells, Cultured; Collagen Type I; Cyclohexanones; DNA; Fibroblasts; Humans; Immunohistochemistry; Keloid; NF-kappa B; Transcription Factor RelA | 2008 |
Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzamides; Cell Line, Tumor; Cell Survival; Cyclohexanones; Herpesvirus 4, Human; Humans; Immunologic Factors; Lymphoproliferative Disorders; Mice; Mice, SCID; NF-kappa B | 2008 |
The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Cyclohexanones; Disease Models, Animal; Intestinal Diseases; Lung Diseases; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2008 |
A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry.
Topics: Animals; Benzamides; Calibration; Chromatography, High Pressure Liquid; Cyclohexanones; Humans; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Reproducibility of Results; Sensitivity and Specificity | 2008 |
Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Blotting, Western; Cell Differentiation; Cell Line; Cyclohexanones; Cyclooxygenase 2; Cytokines; Electrophoretic Mobility Shift Assay; Lipopolysaccharides; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred ICR; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidation-Reduction; Stereoisomerism | 2009 |
Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma; Cyclohexanones; Drug Synergism; Genes, p53; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; NF-kappa B; Peptides; Taxoids; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats.
Topics: Animals; Antibodies; Benzamides; Cell Proliferation; Cyclohexanones; Glomerulonephritis, Membranoproliferative; Kidney Glomerulus; NF-kappa B; Rats; Thy-1 Antigens | 2008 |
Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues.
Topics: Animals; Base Sequence; Benzamides; Binding Sites; Cell Line, Tumor; Cyclohexanones; Cysteine; DNA Primers; Electrophoretic Mobility Shift Assay; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mutagenesis, Site-Directed; NF-kappa B; Surface Plasmon Resonance | 2008 |
Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ).
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Nucleus; Cyclohexanones; Humans; Microscopy, Confocal; NF-kappa B; Protein Transport; Sarcoma, Synovial | 2008 |
Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
Topics: Amino Acid Sequence; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Benzamides; Cell Nucleus; Cyclohexanones; Cysteine; HeLa Cells; Humans; Protein Structure, Tertiary; Sequence Deletion; Transcription Factor RelA | 2008 |
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Rituximab | 2008 |
Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappaB inhibitor (-)-DHMEQ.
Topics: Animals; Benzamides; CCAAT-Enhancer-Binding Protein-beta; Cell Line; Cell Nucleus; Cyclohexanones; Histamine; Histidine Decarboxylase; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; Transcription Factor RelA; Transcriptional Activation | 2009 |
Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Cytochromes c; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; NF-kappa B; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species | 2009 |
Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexanones; Dose-Response Relationship, Drug; Enzyme Activation; HeLa Cells; Herpesvirus 8, Human; Humans; In Situ Nick-End Labeling; Jurkat Cells; K562 Cells; Lymphoma, Primary Effusion; NF-kappa B; Time Factors | 2009 |
A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells.
Topics: Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclohexanones; G2 Phase; Humans; Intercellular Adhesion Molecule-1; Matrix Metalloproteinase 9; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; NF-kappa B; Vascular Endothelial Growth Factor A | 2010 |
Efficient synthesis of (+/-)-parasitenone, a novel inhibitor of NF-kappaB.
Topics: Animals; Benzamides; Cell Line; Cell Proliferation; Cell Survival; Cyclohexanones; Epoxy Compounds; Macrophages; Mice; NF-kappa B; Nitric Oxide | 2009 |
Unusual intramolecular N-->O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine.
Topics: Benzamides; Cyclohexanones; Cysteine; Molecular Conformation; NF-kappa B | 2009 |
Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells.
Topics: Animals; Benzamides; Chlorocebus aethiops; COS Cells; Cyclohexanones; Cytokines; Dendritic Cells; Humans; Interferon-gamma; Ligands; Oligodeoxyribonucleotides; Receptors, IgE; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Autoantibodies; Benzamides; beta 2-Glycoprotein I; Blood Platelets; Cell Line; Cells, Cultured; Chemokine CCL5; Chemokine CX3CL1; Chemokines; Cyclohexanones; Disease Susceptibility; Enzyme-Linked Immunosorbent Assay; Gene Expression; Humans; Leukocytes, Mononuclear; Platelet Activation; Platelet Aggregation; Reverse Transcriptase Polymerase Chain Reaction; Thromboplastin; Thrombosis | 2009 |
Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Camptothecin; Cell Line, Tumor; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Neoplasms; NF-kappa B; Oncogenes | 2009 |
Characterizing the involvement of the nuclear factor-kappa B (NF kappa B) transcription factor in uveal melanoma.
Topics: Apoptosis; Benzamides; Blotting, Western; Caspase 3; Cell Proliferation; Cyclohexanones; Fluorescent Antibody Technique, Indirect; Humans; Imidazoles; Ki-67 Antigen; Liver Neoplasms; Melanoma; NF-kappa B; Quinoxalines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Uveal Neoplasms | 2010 |
Amelioration of experimental autoimmune uveoretinitis with nuclear factor-{kappa}B Inhibitor dehydroxy methyl epoxyquinomicin in mice.
Topics: Animals; Antigen-Presenting Cells; Autoimmune Diseases; Benzamides; Cell Nucleus; Cyclohexanones; Cytokines; Disease Models, Animal; Down-Regulation; Female; Fluorescent Antibody Technique, Indirect; Injections, Intraperitoneal; Lymphocyte Activation; Mice; Microscopy, Confocal; Retina; Retinitis; T-Lymphocytes; Transcription Factor RelA; Uveitis | 2010 |
Gene set enrichment analysis provides insight into novel signalling pathways in breast cancer stem cells.
Topics: Animals; Benzamides; Biomarkers; Breast Neoplasms; CD24 Antigen; Cell Separation; Cyclohexanones; Female; Gene Expression Profiling; Genetic Vectors; Humans; Hyaluronan Receptors; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Oligonucleotide Array Sequence Analysis; Signal Transduction; Transduction, Genetic; Xenograft Model Antitumor Assays | 2010 |
Potent cytotoxic effect of a novel nuclear factor-kappaB inhibitor dehydroxymethylepoxyquinomicin on human bladder cancer cells producing various cytokines.
Topics: Animals; Benzamides; Cyclohexanones; Cytokines; Disease Models, Animal; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
Inhibition of active HIV-1 replication by NF-kappaB inhibitor DHMEQ.
Topics: Anti-HIV Agents; Benzamides; Cell Line; Cells, Cultured; Cyclohexanones; HIV-1; Humans; Immunologic Factors; Leukocytes, Mononuclear; NF-kappa B; Virus Replication | 2010 |
Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1beta-induced human chondrocytes.
Topics: Benzamides; Cartilage, Articular; Cells, Cultured; Chemokine CCL2; Chemokine CCL5; Chondrocytes; Cyclohexanones; Cyclooxygenase 2; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-8; Nitrates; Nitric Oxide Synthase Type II | 2010 |
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Cell Line; Chemokine CCL2; Chemokine CCL5; Cyclohexanones; Histamine; Humans; Hydrocortisone; Inflammation; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-8; Keratinocytes; NF-kappa B | 2010 |
Regulation of human dendritic cells by a novel specific nuclear factor-kappaB inhibitor, dehydroxymethylepoxyquinomicin.
Topics: B7-1 Antigen; B7-2 Antigen; Benzamides; Blotting, Western; CD40 Antigens; Cell Survival; Cells, Cultured; Cyclohexanones; Cytokines; Dendritic Cells; DNA; Dose-Response Relationship, Drug; Flow Cytometry; HLA-DR Antigens; Humans; Interleukin-10; Lipopolysaccharides; Monocytes; NF-kappa B; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes; Th1 Cells; Time Factors | 2010 |
Topical application of dehydroxymethylepoxyquinomicin improves allergic inflammation via NF-kappaB inhibition.
Topics: Active Transport, Cell Nucleus; Administration, Topical; Animals; Benzamides; Cell Line; Cyclohexanones; Dermatitis, Atopic; Disease Models, Animal; Humans; Mice; NF-kappa B | 2010 |
Donor pretreatment with DHMEQ improves islet transplantation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzamides; Caspase 3; Caspase 7; Cyclohexanones; Cytokines; Glucose; Glucose Tolerance Test; In Situ Nick-End Labeling; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Liver; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Tissue Donors; Transplantation, Isogeneic; Transplants | 2010 |
The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma.
Topics: Antibiotics, Antineoplastic; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Cyclohexanones; Doxorubicin; Drug Resistance; Flow Cytometry; Giant Cells; Hodgkin Disease; Humans; Immunohistochemistry; Ki-1 Antigen; Leukocytes, Mononuclear; Microscopy, Fluorescence; Neoplastic Stem Cells; NF-kappa B; Reed-Sternberg Cells | 2010 |
A new NF-κB inhibitor based on the amino-epoxyquinol core of DHMEQ.
Topics: Animals; Benzamides; Cell Line, Tumor; Cyclohexanones; Epoxy Compounds; Hydroquinones; Mice; NF-kappa B; Nitric Oxide; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Hydrogen and N-acetyl-L-cysteine rescue oxidative stress-induced angiogenesis in a mouse corneal alkali-burn model.
Topics: Acetylcysteine; Animals; Antioxidants; Benzamides; Blindness; Burns, Chemical; Chemokine CCL2; Corneal Neovascularization; Cyclohexanones; Deuterium Oxide; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Eye Burns; Male; Mice; Mice, Inbred ICR; Mice, Knockout; Microscopy, Fluorescence; NF-kappa B; Oxidative Stress; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Sodium Hydroxide; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A | 2011 |
Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway.
Topics: Amnion; Animals; Apoptosis; Benzamides; Cyclohexanones; Female; Gestational Age; Macrophages; Mice; Mice, Inbred ICR; NF-kappa B; Peptides, Cyclic; Pregnancy; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Tight Junctions; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factors | 2011 |
Efficient cellular uptake of the novel NF-kappaB inhibitor (-)-DHMEQ and irreversible inhibition of NF-kappaB in neoplastic cells.
Topics: Animals; Benzamides; Cell Survival; Cells, Cultured; Cyclohexanones; Mice; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II | 2010 |
Inhibition of immune activation by a novel nuclear factor-kappa B inhibitor in HTLV-I-associated neurologic disease.
Topics: Benzamides; Cell Proliferation; Cells, Cultured; Cyclohexanones; Drug Evaluation, Preclinical; HeLa Cells; Human T-lymphotropic virus 1; Humans; Immunologic Factors; Immunotherapy; Leukocytes, Mononuclear; Lymphocyte Activation; NF-kappa B; Paraparesis, Tropical Spastic; Signal Transduction; Viral Load | 2011 |
Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Line, Tumor; Cell Separation; Cyclohexanones; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Anti-tumor activity of dehydroxymethylepoxyquinomicin against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cyclohexanones; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Mice; Mouth Neoplasms; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2011 |
Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2.
Topics: Antineoplastic Agents; Antioxidants; Benzamides; Biocatalysis; Burkholderia cepacia; Cell Line, Tumor; Cyclohexanones; Dose-Response Relationship, Drug; Genes, Reporter; Humans; Lipase; Luciferases; Neuroblastoma; NF-E2-Related Factor 2; NF-kappa B; Reactive Oxygen Species; Stereoisomerism | 2011 |
Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Line, Tumor; Cyclohexanones; Disease Progression; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Luminescent Measurements; Mice; Neoplasm Proteins; NF-kappa B; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Fusion Proteins; Spleen; Stromal Cells; Transgenes; Transplantation, Heterologous; Tumor Burden; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2011 |
Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components.
Topics: Benzamides; Biotin; Cyclohexanones; Humans; NF-kappa B; Structure-Activity Relationship | 2011 |
Coffee induces breast cancer resistance protein expression in Caco-2 cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Breast Neoplasms; Caco-2 Cells; Cell Culture Techniques; Coffee; Cyclohexanones; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gene Expression; Humans; Molecular Targeted Therapy; Neoplasm Proteins; NF-kappa B; Plant Extracts | 2011 |
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclohexanones; Glioblastoma; Humans; Male; Mice; Mice, Nude; NF-kappa B; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2012 |
Dehydroxymethylepoxyquinomicin (DHMEQ) can suppress tumour necrosis factor-α production in lipopolysaccharide-injected mice, resulting in rescuing mice from death in vivo.
Topics: Animals; Apoptosis; Benzamides; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cyclohexanones; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shock, Septic; Spleen; Tumor Necrosis Factor-alpha | 2011 |
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
Topics: Benzamides; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Disease-Free Survival; ErbB Receptors; Female; Humans; Interleukin-6; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Plasminogen Activator Inhibitor 1; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Microenvironment; Tyrphostins | 2012 |
A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice.
Topics: Animals; Benzamides; CD4-Positive T-Lymphocytes; Chemokine CCL2; Colitis; Cyclohexanones; Cytokines; Dextran Sulfate; HT29 Cells; Humans; Interleukin-12 Subunit p40; Interleukin-17; Interleukin-1beta; Interleukin-6; Interleukin-8; Macrophages; Male; Mice; Mice, Inbred C57BL; NF-kappa B; RNA, Messenger; Trinitrobenzenesulfonic Acid; Tumor Necrosis Factor-alpha | 2012 |
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Hepatocellular; Celecoxib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclohexanones; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum Stress; fas Receptor; Humans; Liver Neoplasms; NF-kappa B; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Pyrazoles; Reactive Oxygen Species; Repressor Proteins; Sulfonamides | 2012 |
Immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion.
Topics: Animals; Benzamides; Blood Transfusion; Combined Modality Therapy; Cyclohexanones; Graft Survival; H-2 Antigens; Heart Transplantation; Immune Tolerance; Immunologic Factors; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; NF-kappa B; T-Lymphocytes, Regulatory | 2012 |
Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclohexanones; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Methotrexate; Mitotic Index; NF-kappa B; Osteosarcoma; Protein Transport | 2012 |
Involvement of DNA binding domain in the cellular stability and importin affinity of NF-κB component RelB.
Topics: Alanine; Amino Acid Sequence; Arginine; Benzamides; Binding Sites; Cell Nucleus; Cyclohexanones; HeLa Cells; Humans; Karyopherins; Models, Molecular; Molecular Sequence Data; Mutation; Nuclear Localization Signals; Protein Stability; Protein Structure, Tertiary; Protein Transport; Recombinant Proteins; Transcription Factor RelB; Tyrosine | 2012 |
Involvement of NF-κB-mediated expression of galectin-3-binding protein in TNF-α-induced breast cancer cell adhesion.
Topics: Antigens, Neoplasm; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Carrier Proteins; Cell Adhesion; Cell Line, Tumor; Cyclohexanones; Female; Glycoproteins; Humans; NF-kappa B; RNA Interference; RNA, Small Interfering; Tumor Necrosis Factor-alpha | 2012 |
Suppression of inflammatory cytokine secretion by an NF-ĸB inhibitor DHMEQ in nasal polyps fibroblasts.
Topics: Active Transport, Cell Nucleus; Androstadienes; Anti-Inflammatory Agents; Benzamides; Cell Survival; Cells, Cultured; Chemokine CCL5; Cyclohexanones; Cytokines; Fibroblasts; Fluticasone; Gene Expression; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Nasal Polyps; NF-kappa B; Rhinitis; Sinusitis; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2012 |
Enhancement of radiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cyclohexanones; Humans; Male; Mice; Mice, Nude; NF-kappa B; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2012 |
Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodelling in murine models of asthma.
Topics: Airway Remodeling; Animals; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; Cells, Cultured; Cyclohexanones; Cytokines; Disease Models, Animal; Eosinophils; Epithelial Cells; Female; Humans; Inflammation; Inflammation Mediators; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; NF-kappa B; Respiratory Hypersensitivity | 2012 |
A chemo-enzymatic expeditious route to racemic dihexanoyl (2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor for lipase-catalyzed synthesis of the potent nuclear factor-κB inhibitor, (2S,3S,4S)-DHMEQ.
Topics: Benzamides; Benzoquinones; Burkholderia cepacia; Catalysis; Cyclohexanones; Hydroquinones; I-kappa B Proteins; Lipase; NF-KappaB Inhibitor alpha; Oxidation-Reduction; Stereoisomerism | 2012 |
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Movement; Cell Proliferation; Cyclohexanones; Deoxycytidine; Disease Models, Animal; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Interleukin-8; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Topics: Animals; Benzamides; Calcineurin; Calcineurin Inhibitors; Cell Cycle; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Cyclohexanones; Dose-Response Relationship, Drug; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Phosphorylation; Piperidones; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; T-Lymphocytes; Tacrolimus; Time Factors; TOR Serine-Threonine Kinases | 2013 |
Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes.
Topics: Animals; Benzamides; Cells, Cultured; Cyclohexanones; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Endothelial Cells; Male; Mice; NF-kappa B; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Real-Time Polymerase Chain Reaction; Sp1 Transcription Factor | 2013 |
Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Benzamides; Cyclohexanones; Gene Knockdown Techniques; Insulin-Secreting Cells; Insulinoma; Mice; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured | 2013 |
A novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice.
Topics: Adenosine Deaminase; Albuminuria; Animals; Benzamides; Blood Proteins; Cholesterol; Cyclohexanones; Glycerolphosphate Dehydrogenase; Interleukin-6; Intracellular Signaling Peptides and Proteins; Kidney; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Nephrosis; NF-kappa B; Proteinuria; Puromycin Aminonucleoside; Rats; Serum Albumin | 2013 |
Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB suppression via reactive oxygen species and unfolded protein response.
Topics: Animals; Benzamides; Blotting, Northern; Blotting, Western; Cyclohexanones; HEK293 Cells; Humans; Immunoprecipitation; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Rats; Reactive Oxygen Species; Signal Transduction; Transfection; Unfolded Protein Response | 2013 |
Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance.
Topics: Animals; Benzamides; Cyclohexanones; Cytokines; Dendritic Cells; Graft Survival; HMGB1 Protein; Islets of Langerhans Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; NF-kappa B; Postoperative Complications; Tacrolimus; Transplantation, Homologous | 2013 |
Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Topics: Animals; Benzamides; Cyclohexanones; Diabetes Mellitus, Experimental; HMGB1 Protein; Islets of Langerhans Transplantation; Liposomes; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Postoperative Complications; Streptozocin | 2013 |
Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells.
Topics: Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclohexanones; Drug Synergism; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; NF-kappa B; Tumor Cells, Cultured | 2012 |
Inhibition of the NF-κB pathway as a candidate therapeutic strategy for cryopyrin-associated periodic syndrome.
Topics: Benzamides; Cryopyrin-Associated Periodic Syndromes; Cyclohexanones; Cytokines; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes, Mononuclear; NF-kappa B; Signal Transduction | 2014 |
Activation of Akt involves resistance to NF-κB inhibition and abrogation of both triggers synergistic apoptosis in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Aged; Apoptosis; Benzamides; Cell Survival; Cells, Cultured; Cyclohexanones; Drug Synergism; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Multiprotein Complexes; Neoplasm Staging; NF-kappa B; Oncogene Protein v-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Tetrazoles; TOR Serine-Threonine Kinases | 2014 |
Synthesis and evaluation of a cyclopropane derivative of DHMEQ.
Topics: Animals; Benzamides; Cells, Cultured; Cyclohexanones; Cyclooxygenase 2; Cyclopropanes; Mice; NF-kappa B | 2014 |
Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice.
Topics: Animals; Aorta, Thoracic; Arteries; Benzamides; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelium, Vascular; Heart Conduction System; I-kappa B Proteins; Male; Mice; Mice, Knockout; NF-kappa B; Vasodilation | 2015 |
The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
Topics: Antineoplastic Agents; Benzamides; CD40 Antigens; Cell Line, Tumor; Chemokine CCL17; Chemokine CCL5; Cyclohexanones; Down-Regulation; Drug Synergism; Hodgkin Disease; Humans; Interferon Regulatory Factors; Interleukin-6; Ki-1 Antigen; NF-kappa B; Reactive Oxygen Species; Tumor Microenvironment | 2014 |
DSE-FRET: A new anticancer drug screening assay for DNA binding proteins.
Topics: Benzamides; Binding Sites; Cyclohexanones; DNA Probes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Evans Blue; Fluorescence Resonance Energy Transfer; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; NF-kappa B; Recombinant Proteins | 2014 |
Combined inhibition of NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis in melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Cyclohexanones; Drug Synergism; Humans; Indoles; Melanoma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2013 |
Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor.
Topics: Adoptive Transfer; Animals; Arginase; Benzamides; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Culture Media, Conditioned; Cyclohexanones; Dendritic Cells; Female; Humans; Immune Tolerance; Interleukin-6; Interleukin-8; Macrophages; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Signal Transduction; Transcription Factor RelA; Transplantation, Heterologous | 2014 |
Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.
Topics: Antineoplastic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Cyclohexanones; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Transcriptome | 2014 |
Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.
Topics: Animals; Apoptosis; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cholangiocarcinoma; Cyclohexanones; Dose-Response Relationship, Drug; Female; Host-Parasite Interactions; Humans; Immunohistochemistry; Janus Kinase 3; Liver; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; NF-kappa B; Opisthorchiasis; Opisthorchis; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ.
Topics: Animals; Anoikis; Apoptosis Regulatory Proteins; Benzamides; Cell Line, Tumor; Cyclohexanones; Disease Models, Animal; Gene Expression; Genes, Reporter; Humans; Mice; Molecular Imaging; NF-kappa B; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Binding; Transcription Factor RelA; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Nuclear factor-κB activation inhibitor attenuates ischemia reperfusion injury and inhibits Hmgb1 expression.
Topics: Animals; Apoptosis; Benzamides; Cyclohexanones; Glycyrrhizic Acid; Heart Transplantation; HMGB1 Protein; Male; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Neutrophil Infiltration; NF-kappa B; Peroxidase; Reperfusion Injury; Troponin T | 2014 |
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.
Topics: Benzamides; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL2; Corneal Keratocytes; Cyclohexanones; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-8; NF-kappa B; Transcription Factor RelA | 2015 |
Dehydroxymethylepoxyquinomicin selectively ablates T-CAEBV cells.
Topics: Apoptosis; Base Sequence; Benzamides; Cells, Cultured; Chronic Disease; Cyclohexanones; DNA Primers; Epstein-Barr Virus Infections; Flow Cytometry; Gene Expression; Humans; NF-kappa B; Oxidative Stress; Real-Time Polymerase Chain Reaction | 2015 |
Inhibition of canonical NF-κB nuclear localization by (-)-DHMEQ via impairment of DNA binding.
Topics: Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cyclohexanones; DNA; Enzyme Activation; Gene Expression; HeLa Cells; Humans; Leukemia-Lymphoma, Adult T-Cell; Models, Biological; Mutation; NF-kappa B; Protein Binding; Protein Transport; Transcription Factor RelA | 2015 |
Inhibition of MMP-2-Mediated Mast Cell Invasion by NF-κB Inhibitor DHMEQ in Mast Cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Movement; Collagen; Cyclohexanones; Dipeptides; Drug Combinations; Electrophoretic Mobility Shift Assay; Interleukin-6; Laminin; Mast Cells; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; NF-kappa B; Proteoglycans; Rats; Real-Time Polymerase Chain Reaction; RNA; Tumor Necrosis Factor-alpha | 2015 |
A nuclear factor-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrow transplantation.
Topics: Animals; Antibodies; Benzamides; Bone Marrow Transplantation; Cell Proliferation; Cyclohexanones; Cytokines; Graft vs Host Disease; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Receptors, Cell Surface; Spleen; Survival Rate; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2015 |
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Benzamides; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Cisplatin; Cyclohexanones; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Gene Expression; Humans; NF-kappa B | 2016 |
Treatment with novel AP-1 and NF-κB inhibitors restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis.
Topics: Animals; Anti-Inflammatory Agents; Benzamides; Carboxymethylcellulose Sodium; Colitis; Colon; Cyclohexanones; Dextran Sulfate; Disease Models, Animal; Endocrine Cells; Male; NF-kappa B; Piperidones; Rats; Rats, Wistar; Transcription Factor AP-1 | 2016 |
Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzamides; Carboxymethylcellulose Sodium; Colitis; Colon; Cyclohexanones; Dextran Sulfate; Gene Expression Regulation; Lymphocytes; Macrophages; Male; Mast Cells; Monocytes; NF-kappa B; Piperidones; Rats; Rats, Wistar; Signal Transduction; Transcription Factor AP-1; Treatment Outcome | 2016 |
Effects of AP‑1 and NF‑κB inhibitors on colonic endocrine cells in rats with TNBS‑induced colitis.
Topics: Animals; Benzamides; Biomarkers; Body Weight; Chromogranin A; Colitis; Cyclohexanones; Disease Models, Animal; Endocrine Cells; Gene Expression; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; NF-kappa B; Piperidones; Rats; Serotonin; Transcription Factor AP-1; Trinitrobenzenesulfonic Acid | 2016 |
Inhibition of nuclear factor-κB signaling suppresses Spint1-deletion-induced tumor susceptibility in the ApcMin/+ model.
Topics: Adenomatous Polyposis Coli; Animals; Benzamides; Cell Transformation, Neoplastic; Cyclohexanones; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Intestinal Mucosa; Membrane Glycoproteins; Mice, Knockout; Mice, Transgenic; Neoplasms; NF-kappa B; Proteinase Inhibitory Proteins, Secretory; Signal Transduction | 2016 |
Inhibition of MMP-2-mediated cellular invasion by NF-κB inhibitor DHMEQ in 3D culture of breast carcinoma MDA-MB-231 cells: A model for early phase of metastasis.
Topics: Antineoplastic Agents; Benzamides; Breast; Breast Neoplasms; Cell Line, Tumor; Cyclohexanones; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; NF-kappa B; Promoter Regions, Genetic | 2017 |
NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers.
Topics: Benzamides; Cell Line, Tumor; Curcumin; Cyclohexanones; Female; Humans; NF-kappa B; Precision Medicine; Signal Transduction; Triple Negative Breast Neoplasms | 2017 |
External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice.
Topics: Animals; Benzamides; Cyclohexanones; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Epidermis; Mice; Mice, Inbred BALB C; NF-kappa B; Ointments; Oxazolone | 2017 |
Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cyclohexanones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mesenchymal Stem Cells; NF-kappa B; RNA, Small Interfering; Signal Transduction; Tumor Microenvironment | 2018 |
Antineoplastic Effects of NF-κB Inhibition by DHMEQ (Dehydroxymethylepoxyquinomicin) Alone and in Co-treatment with Radio-and Chemotherapy in Medulloblastoma Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Movement; Cell Proliferation; Cyclohexanones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Medulloblastoma; Molecular Structure; NF-kappa B; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
NF‑κB inhibitor DHMEQ inhibits titanium dioxide nanoparticle‑induced interleukin‑1β production: Inhibition of the PM2.5‑induced inflammation model.
Topics: Animals; Benzamides; Biomarkers; Caspase 1; Caspase Inhibitors; Cell Line; Cyclohexanones; Disease Models, Animal; Humans; Inflammation; Interleukin-1beta; Macrophages; Models, Molecular; Nanoparticles; NF-kappa B; Particulate Matter; Potassium; Titanium | 2018 |
Comparison of anti-atopic dermatitis activities between DHMEQ and tacrolimus ointments in mouse model without stratum corneum.
Topics: Animals; Benzamides; Cyclohexanones; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Models, Animal; Epidermis; Female; Humans; Immunoglobulin E; Immunosuppressive Agents; Inflammation Mediators; Mast Cells; Mice; Mice, Inbred BALB C; Ointments; Oxazolone; Tacrolimus | 2019 |
Anti-Inflammatory Effect of Dehydroxymethylepoxyquinomicin, a Nuclear factor-κB Inhibitor, on Endotoxin-Induced Uveitis in Rats In vivo and In vitro.
Topics: Animals; Aqueous Humor; Benzamides; Cells, Cultured; Cyclohexanones; Disease Models, Animal; Immunohistochemistry; Male; NF-kappa B; Rats, Inbred Lew; Treatment Outcome; Uveitis | 2020 |
Role of nuclear factor-kappa B in feline injection site sarcoma.
Topics: Animals; Apoptosis; Benzamides; Cat Diseases; Cats; Cell Line, Tumor; Cyclohexanones; Female; Injection Site Reaction; Male; Sarcoma; Signal Transduction; Transcription Factor RelA | 2019 |
Anti‑inflammatory effects of the NF‑κB inhibitor dehydroxymethylepoxyquinomicin on ARPE‑19 cells.
Topics: Anti-Inflammatory Agents; Apoptosis; Benzamides; Cell Line; Cell Survival; Chemokines; Cyclohexanones; Humans; NF-kappa B; Retinal Pigment Epithelium; Tumor Necrosis Factor-alpha | 2020 |
Upregulation of miRNA‑301a‑3p promotes tumor progression in gastric cancer by suppressing NKRF and activating NF‑κB signaling.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclohexanones; Female; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; NF-kappa B; Prognosis; Repressor Proteins; Signal Transduction; Stomach; Stomach Neoplasms; Up-Regulation | 2020 |
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A nephrotoxicity in a rat model.
Topics: Animals; Benzamides; Cyclohexanones; Cyclosporine; DNA; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; NF-kappa B; Protective Agents; Rats, Sprague-Dawley | 2020 |
Intravenous Administration of Dehydroxymethylepoxyquinomicin With Polymer Enhances the Inhibition of Pancreatic Carcinoma Growth in Mice.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclohexanones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Humans; Mice; Molecular Structure; Polymers; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |